Compare MBLY & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBLY | PEN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.9B |
| IPO Year | 2022 | 2015 |
| Metric | MBLY | PEN |
|---|---|---|
| Price | $10.62 | $312.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $18.94 | ★ $311.25 |
| AVG Volume (30 Days) | ★ 4.2M | 493.7K |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 367.34 |
| EPS | N/A | ★ 4.14 |
| Revenue | ★ $1,938,000,000.00 | $1,333,798,000.00 |
| Revenue This Year | $15.90 | $16.77 |
| Revenue Next Year | $7.88 | $14.12 |
| P/E Ratio | ★ N/A | $75.40 |
| Revenue Growth | 7.61 | ★ 14.61 |
| 52 Week Low | $10.74 | $221.26 |
| 52 Week High | $22.51 | $315.01 |
| Indicator | MBLY | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 67.60 |
| Support Level | $11.17 | $286.75 |
| Resistance Level | $11.88 | $303.00 |
| Average True Range (ATR) | 0.42 | 8.12 |
| MACD | 0.01 | 0.94 |
| Stochastic Oscillator | 2.31 | 88.44 |
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.